ZDF
Sign inSign up

Vulnerabilities

Vulnerability · CVE-2026-41174

Traefik is an HTTP reverse proxy and load balancer.

Published Apr 30, 2026 · catalog updated Jun 17, 2026 · Traefik is an HTTP

Check if you run it

No confirmed exploitation is on record for CVE-2026-41174. EPSS is 0.27%. Act only if a listed version of Traefik is an HTTP is installed.

Gaps on this record

  • The stored product name is a package slug. The name on this page is taken from the title (Traefik is an HTTP).
  • No vendor fix or required action is stored. Compare the linked advisory before you change production.
Severity
Medium4.8
Known exploitation
Not in CISA/VulnCheck KEV
EPSS
0.27%
Remediation
Advisory link
Affected products
cpe traefik/traefik

Traefik is an HTTP reverse proxy and load balancer. Prior to versions 2.11.43, 3.6.14, and 3.7.0-rc.2, there is a potential vulnerability in Traefik's Kubernetes CRD provider cross-namespace isolation enforcement. When providers.kubernetesCRD.allowCrossNamespace=false, Traefik correctly rejects direct cross-namespace middleware references from IngressRoute objects, but fails to apply the same restriction to middleware references nested inside a Chain middleware's spec.chain.middlewares[]. An actor with permission to create or update Traefik CRDs in their own namespace can exploit this to cause Traefik to resolve and apply middleware objects from another namespace, bypassing the documented isolation boundary. This issue has been patched in versions 2.11.43, 3.6.14, and 3.7.0-rc.2.

Are you affected?

Enter the version you run. The result uses only the ranges stored on this record.

The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.

  • cpe traefik/traefik3.7.0

How to fix CVE-2026-41174

What to do

Three questions, each answered from this record only. Confirm the vendor advisory before you patch.

Should you patch?

No confirmed exploitation is on record for CVE-2026-41174. EPSS is 0.27%. Act only if a listed version of Traefik is an HTTP is installed.

Which versions are affected?

Compare what you have installed with 3.7.0. Compare the installed version with the linked vendor advisory before you change production.

What should an analyst verify?

CWE-653; CWE-863: Incorrect Authorization. EPSS 0.27%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.

Code

The project this record applies to. Exploit listings stay in References.

Timeline

Detection, updates, and resolution for this record.

  1. Apr 30, 2026 · NIST NVD

    Detected

    Traefik is an HTTP reverse proxy and load balancer. Prior to versions 2.11.43, 3.6.14, and 3.7.0-rc.2, there is a potential vulnerability in Traefik's Kubernetes CRD provider cross-namespace isolation enforcement. When providers.kubernetesCRD.allowCrossNamespace=false, Traefik correctly rejects direct cross-namespace middleware references from IngressRoute objects, but fails to apply the same rest

  2. Jun 17, 2026 · NIST NVD

    Updated

    Traefik is an HTTP reverse proxy and load balancer. Prior to versions 2.11.43, 3.6.14, and 3.7.0-rc.2, there is a potential vulnerability in Traefik's Kubernetes CRD provider cross-namespace isolation enforcement. When providers.kubernetesCRD.allowCrossNamespace=false, Traefik correctly rejects direct cross-namespace middleware references from IngressRoute objects, but fails to apply the same rest

Sources

  • CVE.orgVulnerability recordCVE-2026-41174

    Official CVE identifier

    cve.org
  • FIRST EPSSExploitation probabilityCVE-2026-41174

    30-day exploitation probability 0.3%

    first.org
  • NIST NVDVulnerability recordCVE-2026-41174

    Traefik is an HTTP reverse proxy and load balancer. Prior to versions 2.11.43, 3.6.14, and 3.7.0-rc.2, there is a potential vulnerability in Traefik's Kubernetes CRD provider cross-namespace isolation enforcement. When providers.kubernetesCRD.allowCrossNamespace=false, Traefik co

    nvd.nist.gov

References

Freshness

Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.